PMID- 29767233
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20181114
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 40
IP  - 1
DP  - 2018 Jul
TI  - Potential role of cyclin F mRNA expression in the survival of skin melanoma
      patients: Comprehensive analysis of the pathways altered due to cyclin F
      upregulation.
PG  - 123-144
LID - 10.3892/or.2018.6435 [doi]
AB  - Cyclin F is a part of the Skp, Cullin, F-box containing ligase complex. The
      activity of cyclin F includes cell cycle control, centrosome duplication and
      response to DNA damage. The cyclin F expression pattern is very similar to cyclin
      A, but cyclin F is an orphan cyclin without its cyclin-dependent kinase partner. 
      There is little evidence concerning the role of cyclin F in cancer. In the
      present study, for the first time, we present analysis from The Cancer Genome
      Atlas (TCGA) data in the context of expression of cyclin F mRNA in melanoma
      patients. Our original in silico analysis, not published elsewhere before,
      revealed that high expression of cyclin F in melanoma patients is associated with
      worse overall survival. Cyclin F and ribonucleotide reductase family member 2
      (RRM2) compose a functional axis responsible for nucleotide metabolism.
      Impairment in this pathway may contribute to increased DNA damage repair and drug
      resistance. Additionally, we analyzed the expression of RRM2 mRNA and discovered 
      that high expression of RRM2 is associated with worse overall survival. To shed
      more light on cyclin F overexpression in melanoma, we analyzed all protein data
      available in the TCGA melanoma dataset. It was found that in patients with
      upregulated cyclin F mRNA, we noted increased activity of pathways related to
      cell cycle and DNA damage repair. These data will support further in vitro and in
      vivo studies on the involvement of cyclin F in skin cutaneous melanoma.
FAU - Gagat, Maciej
AU  - Gagat M
AD  - Department of Histology and Embryology, Faculty of Medicine, Nicolaus Copernicus 
      University in Torun, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland.
FAU - Krajewski, Adrian
AU  - Krajewski A
AD  - Department of Histology and Embryology, Faculty of Medicine, Nicolaus Copernicus 
      University in Torun, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland.
FAU - Grzanka, Dariusz
AU  - Grzanka D
AD  - Department of Clinical Pathomorphology, Faculty of Medicine, Nicolaus Copernicus 
      University in Torun, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland.
FAU - Grzanka, Alina
AU  - Grzanka A
AD  - Department of Histology and Embryology, Faculty of Medicine, Nicolaus Copernicus 
      University in Torun, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20180516
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (CCNF protein, human)
RN  - 0 (Cyclins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - EC 1.17.4.- (ribonucleotide reductase M2)
RN  - EC 1.17.4.1 (Ribonucleoside Diphosphate Reductase)
RN  - EC 2.3.2.27 (SKP Cullin F-Box Protein Ligases)
RN  - Melanoma, Cutaneous Malignant
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cell Division/genetics
MH  - Cyclins/*genetics
MH  - DNA Damage/genetics
MH  - DNA Repair/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Melanoma/epidemiology/*genetics/pathology
MH  - Middle Aged
MH  - Neoplasm Proteins/*genetics
MH  - RNA, Messenger/genetics
MH  - Ribonucleoside Diphosphate Reductase/*genetics
MH  - SKP Cullin F-Box Protein Ligases/genetics
MH  - Skin Neoplasms/epidemiology/*genetics/pathology
MH  - Transcriptional Activation/genetics
PMC - PMC6059736
EDAT- 2018/05/17 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/05/17 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/05/03 00:00 [accepted]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/05/17 06:00 [entrez]
AID - 10.3892/or.2018.6435 [doi]
PST - ppublish
SO  - Oncol Rep. 2018 Jul;40(1):123-144. doi: 10.3892/or.2018.6435. Epub 2018 May 16.